Genetic Technologies EPS - Earnings per Share 2010-2021 | GENE
Genetic Technologies eps - earnings per share from 2010 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Genetic Technologies Annual EPS |
2021 |
$-0.36 |
2020 |
$-0.60 |
2019 |
$-1.05 |
2018 |
$-1.02 |
2017 |
$-1.79 |
2016 |
$-2.16 |
2015 |
$-4.12 |
2014 |
$-9.60 |
2013 |
$-12.20 |
2012 |
$-7.20 |
2011 |
$1.40 |
2010 |
$-13.00 |
2009 |
$-0.20 |
Genetic Technologies Quarterly EPS |
2021-12-31 |
$0.00 |
2021-06-30 |
$0.00 |
2020-12-31 |
$0.00 |
2020-06-30 |
$0.00 |
2019-12-31 |
$0.00 |
2019-06-30 |
$0.00 |
2018-12-31 |
$0.00 |
2018-06-30 |
$0.00 |
2017-12-31 |
$0.00 |
2017-06-30 |
$0.00 |
2016-12-31 |
$0.00 |
2016-06-30 |
$0.00 |
2015-12-31 |
$0.00 |
2015-06-30 |
$0.00 |
2014-12-31 |
$0.00 |
2014-06-30 |
$0.00 |
2013-12-31 |
$0.00 |
2013-06-30 |
$0.00 |
2012-12-31 |
$0.00 |
2012-06-30 |
$0.00 |
2011-12-31 |
$0.00 |
2011-06-30 |
$0.00 |
2010-12-31 |
$0.00 |
2010-06-30 |
$0.00 |
2009-12-31 |
$0.00 |
2009-06-30 |
$0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.020B |
$0.000B |
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
|